ACT2 Study
The University Of Birmingham Complete Transparency notice
- Buyer
- The University Of Birmingham
- Awarded value
- £515,318 excluding VAT where the notices give it
- Procedure
- Direct award
- Category
- Services
- CPV code
85141000Services provided by medical personnel- First published
- 14 Jul 2025
- Last updated
- 14 Jul 2025
- Legal basis
- Procurement Act 2023
Description
University of Birmingham (UoB) is the sponsor of ACT2 (Allogeneic Chondrocyte Therapy - A phase 2a study), an MRC funded project (MR/V027670/1). The study commenced in 2021 with the aim to develop and manufacture an allogeneic chondroprogenitor cell therapy from fresh osteochondral allografts in order to treat cartilage lesions in a single surgery. The study requires a manufacturing facility that can work with the research team to develop and validate the manufacturing process of the cell therapy product to a standard that can gain MHRA approval and thus enable the commencement of a Phase 2a human trial. Due to unforeseen circumstances, previously contracted GMP manufacturers are no longer able to manufacture the cell therapy product and, thus an alternative manufacturing facility is required expeditiously.
The UoB team must operate within the restrictions placed upon them by the funder and the current project plan. In addition to this, the administrative burden as a consequence of BREXIT makes the use of a UK laboratory the only viable option. The Newcastle Advanced Therapies Facility has the unique requirements to deliver the project within the financial and time restrictions facing the project.
Awards
| Supplier | Value | Date | Status |
|---|---|---|---|
| Newcastle Hospitals NHS Foundation Trust (Newcastle Advanced Therapies) | £515,318 | 14 Jul 2025 | Pending |
Notices
- 14 Jul 2025 Transparency notice 039471-2025
Find a Tender holds the official notices, with their documents and contact details.